THE PREVENTION OF PULMONARY EMBOLISM

Abstract

Coronavirus infection (COVID-19), an acute infectious disease caused by the SARS-CoV-2 virus, is characterized by activation of the hemostasis system, which in the most severe cases can lead to the development of consumption coagulopathy. At present, it remains unclear whether COVID-19 is the direct cause of these disorders or they arise as the infectious process progresses. In COVID-19, the incidence of asymptomatic and clinically pronounced thrombotic/thromboembolic complications (TEC) remains unclear, which is largely due to the difficulties of their diagnosis (problems of instrumental examination of patients lying on their stomach, the desire to limit the involvement of additional equipment and personnel). At the same time, according to some reports, the frequency of venous and arterial thrombosis in severely ill COVID-19 patients is quite high. Thus, in 184 patients with pneumonia with COVID-19, who was in intensive care units of 3 hospitals in Denmark, 13% of whom died, symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), ischemic stroke, myocardial infarction, or arterial thromboembolism noted in 31% of cases.